Full-Time

Global Process Owner

People Strategy and Human Capital Management

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Expert

Paris, France + 2 more

More locations: Hyderabad, Telangana, India | Sant Cugat del Vallès, Barcelona, Spain

Hybrid work model; candidates may need to work in-office a few days a week.

Category
Human Resources
People & HR
Required Skills
Agile
Data Analysis
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Sanofi referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Deep expertise (10+ years of experience) in leading process innovation and standardization, stakeholder engagement, and the ability to navigate complex organizational structures to drive business-aligned modernization and globalization of Human Capital Management processes
  • Functional knowledge of Human Capital Management processes, policies and principles
  • Demonstrated experience in optimizing processes leveraging well known process excellence methodologies (i.e., Agile, Lean 6 Sigma, etc.)
  • Green Belt certification or equivalent required; Black Belt preferred
  • Ability to engage, align, and drive change across multiple stakeholder groups, and influence change across all levels of the organization
  • Exceptional experience in problem solving and continuous improvement to support the evolving needs of our organization
  • Proven experience in designing and implementing global P&C processes, considering cultural nuances and regional differences
  • Strong analytical skills to measure and analyze performance data to drive decision-making
  • Excellent communication and stakeholder management skills to collaborate effectively with cross-functional teams across different locations
Responsibilities
  • Own and define the vision and strategy for the evolution of Human Capital Management processes in alignment with P&C priorities and business objectives
  • Lead and manage the end-to-end process ownership for Human Capital Management driving process standardization, excellence, optimization and innovation
  • Alongside peer GPOs, establish and adhere to a governance framework that ensures consistent decision making across standardization, compliance and operational excellence
  • Champion process innovation by identifying opportunities to leverage emerging technologies and best practices
  • Harness data and analytics to track and assess the efficiency, effectiveness and experience of relevant processes, while also uncovering root cause, opportunities and innovation for improvement
  • Lead cross-functional collaboration to optimize end-to-end processes, ensuring scalability and adaptability in a fast-changing markets
  • Utilize relevant process excellence methodologies (e.g. Lean Six Sigma) to drive continuous innovation and improvement
  • Collaborate closely with global P&C, leaders and local teams to address specific needs and challenges
  • Communicate process updates and lead relevant change initiatives effectively to all stakeholders across the organization
  • Act as a trusted advisor to CoE leadership on industry trends and best practices
  • Champion and influence change within P&C and at cross functional – at global and local / market level where required

Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new therapies for conditions like immunology, oncology, and rare diseases. Their products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. Sanofi distinguishes itself from competitors by its strong emphasis on R&D and strategic partnerships, allowing it to maintain a diverse pipeline of new products. The company's goal is to enhance health outcomes and improve the quality of life for people globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi reported a 20% profit growth in Q1 2025, driven by Dupixent and new launches.
  • The FDA approved Dupixent for chronic spontaneous urticaria, expanding its treatment indications.
  • Sanofi's investment in Innate Pharma supports its strategic goals in oncology.

What critics are saying

  • Increased competition in immunology could impact Dupixent's market share.
  • Potential delays in EU approval for tolebrutinib may affect market entry.
  • The Dren Bio acquisition may not yield expected financial returns.

What makes Sanofi unique

  • Sanofi's Dupixent is the first targeted therapy for chronic spontaneous urticaria.
  • Tolebrutinib is a potential first-in-class therapy for non-relapsing secondary progressive multiple sclerosis.
  • Sanofi's acquisition of Dren Bio enhances its biopharmaceutical capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.

Yahoo Finance
Apr 24th, 2025
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%

PharmiWeb
Apr 24th, 2025
Dupixent Approved In The Us As The First New Targeted Therapy In Over A Decade For Chronic Spontaneous Urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks

PharmiWeb
Apr 9th, 2025
Tolebrutinib Phase 3 Data Published In Nejm Demonstrate Benefit On Disability Progression In Multiple Sclerosis

Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved. These findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity. These results were first presented at the ECTRIMS conference on September 20, 2024 in Copenhagen, Denmark and further analyses were also presented today during the Clinical Trials Plenary Session at the 2025 Annual Meeting for the American Academy of Neurology (AAN) in San Diego, California.Robert Fox, MDVice Chair of Research at Cleveland Clinic’s Neurological Institute, Cleveland, Ohio, US, and chair of the HERCULES global steering committee“Tolebrutinib represents a new class of therapy for the treatment of multiple sclerosis. In this large phase 3 study, tolebrutinib was found to slow the progression of disability in a subset of multiple sclerosis for which we have no approved therapies – non-relapsing secondary progressive disease. The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.”Dr Fox is a paid advisor to Sanofi for the HERCULES study.Erik Wallström, MD, PhDGlobal Head of Neurology Development“By targeting disability progression mechanisms behind the blood-brain barrier, tolebrutinib has the potential to be a practice-changing therapeutic option for people living with multiple sclerosis

PharmiWeb
Mar 25th, 2025
Availability Of The Q1 2025 Aide Mémoire

Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website:First quarter 2025 (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter 2025 results will be published on April 24, 2025.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comEvan Berland | + 1 215 432 0234 | evan.berland@sanofi.comNicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.comLéo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.comVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.comInvestor RelationsThomas Kudsk Larsen | + 44 75 45 51 36 93| thomas.larsen@sanofi.comAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comKeita Browne | +1 781 249 1766 | keita.browne@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.comThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.comYun Li | + 33 6 84 00 90 72 | yun.li3@sanofi.comForward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended